Page 10 - Read Online
P. 10

Fenton et al. Cancer Drug Resist 2018;1:200-3 I                                                          Page 203

               15.  Sawada T, Hirayama M, Nakata T, Takeda T, Takasugi N, et al. Mass screening for neuroblastoma in infants in Japan. Interim report of a
                   mass screening study group. Lancet 1984;324:271-3.
               16.  Shinagawa T, Kitamura T, Katanoda K, Matsuda T, Ito Y, et al. The incidence and mortality rates of neuroblastoma cases before and
                   after the cessation of the mass screening program in Japan: a descriptive study. Int J Cancer 2017;140:618-25.
               17.  Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2013:CD001877.
               18.  Bleyer A. Screening mammography: update and review of publications since our report in the New England Journal of Medicine on the
                   magnitude of the problem in the United States. Acad Radiol 2015;22:949-60.
               19.  Ripping TM, Ten Haaf K, Verbeek ALM, van Ravesteyn NT, Broeders MJM. Quantifying overdiagnosis in cancer screening: a
                   systematic review to evaluate the methodology. J Natl Cancer Inst 2017;109: doi: 10.1093/jnci/djx060.
               20.  Wallis MG. How do we manage overdiagnosis/overtreatment in breast screening? Clin Radiol 2018;73:372-80.
               21.  DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res 2008;68:8643-53.
               22.  Zaffiri L, Gardner J, Toledo-Pereyra LH. History of antibiotics. From salvarsan to cephalosporins. J Invest Surg 2012;25:67-77.
               23.  Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer
               24.  Zaffiri L, Gardner J, Toledo-Pereyra LH. History of antibiotics: from fluoroquinolones to daptomycin (Part 2). J Invest Surg
               25.  De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev 2016;29:695-747.
               26.  Sachs JR, Mayawala K, Gadamsetty S, Kang SP, de Alwis DP. Optimal dosing for targeted therapies in oncology: drug development
                   cases leading by example. Clin Cancer Res 2016;22:1318-24.
               27.  Wong KM, Capasso A, Eckhardt SG. The changing landscape of phase I trials in oncology. Nat Rev Clin Oncol 2016;13:106-17.
               28.  McCarthy MW, Kontoyiannis DP, Cornely OA, Perfect JR, Walsh TJ. Novel agents and drug targets to meet the challenges of resistant
                   fungi. J Infect Dis 2017;216:S474-83.
               29.  Gatzka MV. Targeted tumor therapy remixed-an update on the use of small-molecule drugs in combination therapies. Cancers (Basel)
               30.  Kavanagh S, Nee A, Lipton JH. Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia. Expert Opin
                   Emerg Drugs 2018;23:51-62.
               31.  Kleczko EK, Heasley LE. Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and
                   inherent therapeutic vulnerabilities. Mol Cancer 2018;17:60.
               32.  Larionov AA. Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients. Front Oncol
               33.  Sharma GG, Mota I, Mologni L, Patrucco E, Gambacorti-Passerini C, et al. Tumor resistance against ALK targeted therapy-where it
                   comes from and where it goes. Cancers (Basel) 2018;10:E62.
               34.  Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine
                   kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer 2018;17:49.
               35.  Tomasello C, Baldessari C, Napolitano M, Orsi G, Grizzi G, et al. Resistance to EGFR inhibitors in non-small cell lung cancer: clinical
                   management and future perspectives. Crit Rev Oncol Hematol 2018;123:149-61.
               36.  Bock C, Lengauer T. Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer 2012;12:494-501.
               37.  Garbelli A, Riva V, Crespan E, Maga G. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher? Biochem
                   J 2017;474:1559-77.
               38.  Britt WJ, Prichard MN. New therapies for human cytomegalovirus infections. Antiviral Res 2018;159:153-74.
               39.  Hamers RL, Rinke de Wit TF, Holmes CB. HIV drug resistance in low-income and middle-income countries. Lancet HIV
               40.  Anderson R, Rapoport BL. Immune dysregulation in cancer patients undergoing immune checkpoint inhibitor treatment and potential
                   predictive strategies for future clinical practice. Front Oncol 2018;8:80.
               41.  Davis MP, Panikkar R. Checkpoint inhibitors, palliative care, or hospice. Curr Oncol Rep 2018;20:2.
               42.  Li X, Shao C, Shi Y, Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol
   5   6   7   8   9   10   11   12   13   14   15